356 related articles for article (PubMed ID: 25157767)
41. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
[TBL] [Abstract][Full Text] [Related]
42. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
43. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
44. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
45. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
[TBL] [Abstract][Full Text] [Related]
46. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
47. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
48. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.
Govindan R; Bogart J; Stinchcombe T; Wang X; Hodgson L; Kratzke R; Garst J; Brotherton T; Vokes EE
J Clin Oncol; 2011 Aug; 29(23):3120-5. PubMed ID: 21747084
[TBL] [Abstract][Full Text] [Related]
49. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Mencoboni M; Botta M; Grossi F; Cortinovis D; Zilembo N; Ripa C; Tiseo M; Favaretto AG; Soto-Parra H; De Vincenzo F; Bruzzone A; Lorenzi E; Gianoncelli L; Ercoli B; Giordano L; Santoro A
Br J Cancer; 2013 Aug; 109(3):552-8. PubMed ID: 23860535
[TBL] [Abstract][Full Text] [Related]
50. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
51. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y; Kishimoto J; Sugawara S; Mizutani H; Daga H; Azuma K; Matsumoto H; Hataji O; Nishino K; Mori M; Shukuya T; Saito H; Tachihara M; Hayashi H; Tsuya A; Wakuda K; Yanagitani N; Sakamoto T; Miura S; Hata A; Okada M; Kozuki T; Sato Y; Harada T; Takayama K; Yamamoto N; Nakagawa K; Okamoto I
JAMA Oncol; 2024 Mar; 10(3):315-324. PubMed ID: 38127362
[TBL] [Abstract][Full Text] [Related]
52. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.
Gervais R; Robinet G; Clément-Duchêne C; Denis F; El Kouri C; Martin P; Chouaki N; Bourayou N; Morère JF
Lung Cancer; 2013 May; 80(2):185-90. PubMed ID: 23434351
[TBL] [Abstract][Full Text] [Related]
53. Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.
Okamoto I; Aoe K; Kato T; Hosomi Y; Yokoyama A; Imamura F; Kiura K; Hirashima T; Nishio M; Nogami N; Okamoto H; Saka H; Yamamoto N; Yoshizuka N; Sekiguchi R; Kiyosawa K; Nakagawa K; Tamura T
Invest New Drugs; 2013 Oct; 31(5):1275-82. PubMed ID: 23475281
[TBL] [Abstract][Full Text] [Related]
54. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
[TBL] [Abstract][Full Text] [Related]
55. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
56. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
[TBL] [Abstract][Full Text] [Related]
57. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
Ramalingam SS; Dahlberg SE; Belani CP; Saltzman JN; Pennell NA; Nambudiri GS; McCann JC; Winegarden JD; Kassem MA; Mohamed MK; Rothman JM; Lyss AP; Horn L; Stinchcombe TE; Schiller JH
J Clin Oncol; 2019 Sep; 37(26):2360-2367. PubMed ID: 31361535
[TBL] [Abstract][Full Text] [Related]
58. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
[TBL] [Abstract][Full Text] [Related]
59. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.
Zhang GZ; Jiao SC; Meng ZT
J Exp Clin Cancer Res; 2010 Apr; 29(1):38. PubMed ID: 20423465
[TBL] [Abstract][Full Text] [Related]
60. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
